A5007544977- Health Systems, Economic Evaluations, Quality of Life
- Healthcare cost, quality, practices
- Healthcare Systems and Reforms
- Healthcare Policy and Management
- Global Health Care Issues
- Pharmaceutical Economics and Policy
- Global Public Health Policies and Epidemiology
- Global Maternal and Child Health
- Primary Care and Health Outcomes
- Clinical practice guidelines implementation
- Health Policy Implementation Science
- Economic and Financial Impacts of Cancer
- Delphi Technique in Research
- Global Cancer Incidence and Screening
- HIV/AIDS Impact and Responses
- Meta-analysis and systematic reviews
- Health and Medical Research Impacts
- Economic and Environmental Valuation
- COVID-19 epidemiological studies
- Quality and Safety in Healthcare
- Child and Adolescent Health
- Vaccine Coverage and Hesitancy
- Blood Pressure and Hypertension Studies
- Healthcare Systems and Challenges
- Pharmaceutical industry and healthcare
Imperial College London
2016-2025
World Health Organization
2025
London International Development Centre
2018-2023
Global Fund to Fight AIDS, Tuberculosis and Malaria
2021-2023
Bocconi University
2022-2023
Center for Global Development
2017-2022
Right to Care
2022
University of Maryland, College Park
2021
University of York
2012-2021
St Mary's Hospital
2020
Randomized trials have traditionally been broadly categorized as either an effectiveness trial or efficacy trial, although we prefer the terms "pragmatic" and "explanatory." Schwartz Lellouch described these 2 approaches toward clinical in 1967. [1][1] These authors coined
Abstract Background Stakeholder engagement has become widely accepted as a necessary component of guideline development and implementation. While frameworks for developing guidelines express the need those potentially affected by recommendations to be involved in their development, there is lack consensus on how this should done practice. Further, guidance equitably meaningfully engage multiple stakeholders. We aim develop meaningful equitable stakeholders Methods This will multi-stage...
Context: The discussion about improving the efficiency, quality, and long‐term sustainability of U.S. health care system is increasingly focusing on need to provide better evidence for decision making through comparative effectiveness research (CER). In recent years, several other countries have established agencies evaluate technologies broader management strategies inform policy decisions. This article reviews experiences from Britain, France, Australia, Germany. Methods: draws experience...
There is a growing appreciation that our current approach to clinical research leaves important gaps in evidence from the perspective of patients, clinicians, and payers wishing make evidence-based health policy decisions. This has been major driver rapid increase interest comparative effectiveness (CER), which aims compare benefits, risks, sometimes costs alternative health-care interventions 'the real world'. While broad range experimental nonexperimental methods will be used conducting...
In the context of health systems, priority-setting is about allocation resources to innovative high-cost medicines or new vaccines and its introduction in public programmes; prevention, primary care; training community Abstract Governments low-and middle-income countries are legitimizing implementation universal coverage (UHC), following a United Nation's resolution on UHC 2012 reinforcement sustainable development goals set 2015.UHC will differ each country depending contexts needs, as well...
Distributional cost-effectiveness analysis (DCEA) provides information about the equity impacts of health technologies and programs trade-offs that sometimes arise between efficiency. This field has now come age with a growing applied literature,1 new training resources,2 formal professional network: special interest group on equity-informative economic evaluation within International Health Economics Association.3
The rationing problem is common to all health systems-the challenge of managing finite resources address unlimited demand for services. In most low- and middle-income countries, occurs as an ad hoc, haphazard series nontransparent choices that reflect the competing interests governments, donors, other stakeholders. Yet in a growing number more explicit processes, with strengths limitations, are under development merit better support. Against this background, purpose Center Global Development...
<ns4:p>Health Technology Assessment (HTA) is policy research that aims to inform priority setting and resource allocation. HTA increasingly recognized as a useful tool in low- middle-income countries (LMICs), where there substantial need for evidence guide Universal Health Coverage policies, such benefit coverage, quality improvement interventions standards, all of which aim at improving the efficiency equity healthcare system.</ns4:p><ns4:p> The Intervention Program (HITAP), Thailand,...
Resource allocation in health is universally challenging, but especially so resource-constrained contexts the Global South. Pursuing a strategy of evidence-based decision-making and using tools such as Health Technology Assessment (HTA), can help address issues relating to both affordability equity when allocating resources. Three BRICS South countries, China, India Africa have committed strengthening HTA capacity developing their domestic systems, with goal getting evidence translated into...
<ns4:p>Public payers around the world are increasingly using cost-effectiveness thresholds (CETs) to assess value-for-money of an intervention and make coverage decisions. However, there is still much confusion about meaning uses CET, how it should be calculated, what constitutes adequate evidence base for its formulation. One widely referenced used threshold in last decade has been 1-3 GDP per capita, which often attributed Commission on Macroeconomics WHO guidelines Choosing Interventions...
We discuss the challenge of managing innovation in and access to health care interventions an evidence-based, cost-effective way, we describe a decision-making framework (using U.S. U.K. case studies) for payers considering adoption new technologies. argue that providing reimbursement what could be technology "only context research" will appropriate if costs delaying implementation are offset by value "keeping one's options open" waiting more information. conclude there is need better...